Biospecimen Data & Data Management Services
Having robust, accurate specimen data sets is a critical priority for researchers. iSpecimen leverages deep expertise and our technology to deliver on exacting data requirements while ensuring data integrity.
We collect and harmonize de-identified patient data directly from laboratory information systems and medical records, managing compliance and ethics at every step of the way.
Through an iSpecimen Marketplace® account, the customer has access to customizable biospecimen datasets—anytime and anywhere.
How iSpecimen is Increasing Data Accessibility
iSpecimen has connections to a variety of de-identified data sources such as electronic medical record (EMR) systems, laboratory information systems (LIS), laboratory information management systems (LIMS), Health Information Exchange (HIE) records, and other patient records. This expands the data while eliminating human errors that occur when manually extracting information.
Our biospecimen data offerings:
1
Patient demographics
Our technology allows researchers to glean more information from the patient than ever before. Using the electronic medical record, iSpecimen provides researchers with the target patient’s age, gender, ethnicity, race, geography, and more.
2
Conditions, treatments & outcomes
Our technology enables biospecimen matching, made possible via access to robust de-identified patient and specimen data. In the iSpecimen Marketplace, one can filter by potentially comorbid medical conditions, types of medications with outcomes data, disease stage, and histological diagnosis.
3
Testing & collection information
Within the iSpecimen Marketplace, researchers can also refine their sample search by the patient’s testing history, which may include molecular and genetic test data. Data such as specimen collection year, collection procedure, and test methodologies are also available.
4
QA characteristics
To aid in selecting appropriate biospecimens, researchers can view quality assurance characteristics such as the volume and size of the sample, the quantified percentage of tumor, or percentage of necrosis that is present in the sample.
5
Family & social history
Our deep access to de-identified patient data permits a view into the ways in which the patients’ social network has impacted their health. For example, our specimen data indicates both lifestyle choices, such as recent international travel, smoking status, etc. and family-related health impacts such as pregnancy status and hereditary diseases.